Guanfacine and ADHD

How guanfacine works

Guanfacine targets alpha-2A adrenergic receptors in the prefrontal cortex, the part of the brain responsible for attention, working memory, and impulse control. Unlike stimulants, which increase dopamine and norepinephrine across multiple brain systems, guanfacine acts more selectively on the prefrontal circuits most directly affected in ADHD.

This targeted mechanism is why guanfacine is particularly useful for symptoms that stimulants do not fully address: emotional dysregulation, impulsivity, and hyperactivity that persists even on stimulant medication.

Because it works through a different pathway entirely, guanfacine can be prescribed alongside stimulant medication when stimulants alone are insufficient. ADHDose tracks guanfacine as a separate medication and shows how your daily patterns compare to your logged baseline.

Why guanfacine is prescribed

In the UK, guanfacine extended-release (Intuniv) is licensed for ADHD in children and adolescents aged 6 to 17, either as a standalone medication or as an adjunct to stimulant treatment.

It is typically considered when stimulant medications are not well tolerated, when stimulants provide insufficient benefit on their own, or when specific symptoms such as tics, sleep difficulties, or emotional dysregulation are prominent alongside the core ADHD presentation.

It is also sometimes prescribed for adults with ADHD when stimulants are contraindicated, though the licensed age indication is 6 to 17 and adult prescribing is off-label in the UK.

The first few weeks

Guanfacine does not work on the first dose. Unlike stimulants, which provide an effect within hours, guanfacine requires gradual dose titration and builds up over several weeks. Most prescribers begin at 1mg and increase slowly, with a review after each adjustment.

Common early side effects include drowsiness, fatigue, and reduced blood pressure. These often settle within the first two to four weeks. Taking guanfacine in the evening can reduce daytime drowsiness, though your prescriber will advise on timing.

Because there is no immediate daily effect to observe, tracking your experience through titration with ADHDose gives you and your prescriber a cleaner picture of how each dose level is affecting your focus, sleep, and mood over the weeks.

Guanfacine and sleep

Guanfacine has a more direct effect on sleep than most ADHD medications. Sedation is one of its most common side effects. For some people this is useful: prescribers sometimes recommend guanfacine specifically because it can improve sleep onset in children with ADHD who have significant sleep difficulties alongside their daytime symptoms.

For others, daytime drowsiness is a significant side effect that requires adjusting the timing of the dose or reducing the amount. ADHDose lets you log your sleep quality and daytime alertness so you can track whether the timing adjustment makes a difference.

Using guanfacine alongside stimulant medication

The combination of guanfacine and a stimulant is increasingly common in specialist ADHD practice. Stimulants address the dopamine/norepinephrine deficit that drives inattention; guanfacine targets the prefrontal alpha-2 circuits that govern impulse control and emotional regulation.

If you are taking both, ADHDose treats them as separate substances and allows you to track how both your stimulant and your daily guanfacine are fitting together over time. Your prescriber will want to know how the combination is affecting your sleep, mood, and daily function across several weeks.

How ADHDose works with guanfacine

Guanfacine does not produce the daily peak-and-trough concentration curve that stimulants do, so ADHDose does not show a concentration chart for guanfacine. What it does provide is a daily journal for tracking focus quality, sleep, mood, and side effects throughout your titration period.

The Clinician Summary feature generates an appointment-ready overview of your logged data, showing your prescriber how each dose level has affected your day-to-day experience across the weeks between reviews. For a medication that builds slowly and whose effects require weeks of data to evaluate, this documentation is particularly valuable.